Balance Sheet Arrowhead Pharmaceuticals, Inc.

Equities

ARWR

US04280A1007

Biotechnology & Medical Research

Real-time Estimate Cboe BZX Other stock markets 16:36:40 14/07/2025 BST			5-day change	1st Jan Change
18.87 ^USD	+3.06%		+11.82%	+0.16%

07-08	Arrowhead Pharmaceuticals, Inc., Q2 2025 Earnings Call, May 12, 2025
07-08	Arrowhead Pharmaceuticals Initiates Phase 3 YOSEMITE Study of Investigational Zodasiran for the Treatment of Homozygous Familial Hypercholesterolemia	CI

734aa5.JYbang0hC9jUxcClns06rFXF-uogthXSbo01nMNPWZk.dOq_zHxQPZmY9I_TzJdS6QCyirxL8XK2G_QD97Eaatt0q7b2e0laq4Gs9A

Published financial data: ARROWHEAD PHARMACEUTICALS, INC.

Annual

Quarterly

Halfyear

YTD

LTM

Fiscal Period: September	2020	2021	2022	2023	2024
Revenues	87.99M	138M	243M	241M	3.55M
Total Revenues	87.99M	138M	243M	241M	3.55M
Gross Profit	87.99M	138M	243M	241M	3.55M
Selling General & Admin Expenses, Total	56.41M	88.68M	137M	109M	125M
Stock-Based Compensation (IS)	-	-	-	-	-
R&D Expenses	125M	199M	284M	337M	480M
Depreciation & Amortization - (IS)	-	-	-	-	-
Other Operating Expenses, Total	181M	287M	422M	446M	605M
Operating Income	-93.16M	-149M	-179M	-205M	-601M
Interest Expense, Total	-	-	-	-18.33M	-32.35M
Interest And Investment Income	9.19M	6.12M	5.03M	15.3M	22.72M
Net Interest Expenses	9.19M	6.12M	5.03M	-3.03M	-9.63M
Other Non Operating Income (Expenses)	-583K	2.07M	5.2M	1.54M	-1.75M
EBT, Excl. Unusual Items	-84.55M	-141M	-168M	-206M	-612M
Gain (Loss) On Sale Of Investments	-	-	-4.43M	-	-
Gain (Loss) On Sale Of Assets	-	-	-	-	-
Asset Writedown	-	-	-	-	-
In Process R&D Expenses	-	-	-	-	-
Insurance Settlements	-	-	-	-	-
Other Unusual Items	-	-	-	-	-
EBT, Incl. Unusual Items	-84.55M	-141M	-173M	-206M	-612M
Income Tax Expense	2.4K	2K	3.78M	2.78M	-2.77M
Earnings From Continuing Operations	-84.55M	-141M	-176M	-209M	-610M
Net Income to Company	-84.55M	-141M	-176M	-209M	-610M
Minority Interest	-	-	431K	4M	10.2M
Net Income - (IS)	-84.55M	-141M	-176M	-205M	-599M
Net Income to Common Incl Extra Items	-84.55M	-141M	-176M	-205M	-599M
Net Income to Common Excl. Extra Items	-84.55M	-141M	-176M	-205M	-599M
Per Share Items
Net EPS - Basic	-0.84	-1.36	-1.67	-1.92	-5
Basic EPS - Continuing Operations	-0.84	-1.36	-1.67	-1.92	-5
Basic Weighted Average Shares Outstanding	101M	104M	105M	107M	120M
Net EPS - Diluted	-0.84	-1.36	-1.67	-1.92	-5
Diluted EPS - Continuing Operations	-0.84	-1.36	-1.67	-1.92	-5
Diluted Weighted Average Shares Outstanding	101M	104M	105M	107M	120M
Normalized Basic EPS	-0.52	-0.85	-0.99	-1.17	-3.11
Normalized Diluted EPS	-0.52	-0.85	-0.99	-1.17	-3.11
American Depositary Receipts Ratio (ADR)	0.12	0.12	0.12	0.12	0.12
Supplemental Items
EBITDA	-87.22M	-141M	-168M	-193M	-582M
EBITA	-91.46M	-147M	-177M	-203M	-599M
EBIT	-93.16M	-149M	-179M	-205M	-601M
EBITDAR	-80.88M	-131M	-152M	-173M	-553M
Effective Tax Rate - (Ratio)	-0	-0	-2.19	-1.35	0.45
Current Domestic Taxes	2.4K	2K	304K	2.78M	523K
Current Foreign Taxes	-	-	3.48M	-	-3.29M
Total Current Taxes	2.4K	2K	3.78M	2.78M	-2.77M
Normalized Net Income	-52.84M	-88.03M	-105M	-125M	-373M
Supplemental Operating Expense Items
General and Administrative Expenses	52.28M	78.64M	122M	89.13M	94.64M
Research And Development Expense From Footnotes	129M	206M	297M	353M	506M
Net Rental Expense, Total	6.34M	10.04M	15.86M	19.68M	29.9M
Imputed Operating Lease Interest Expense	-	-	-	12.41M	12.53M
Imputed Operating Lease Depreciation	-	-	-	7.27M	17.37M
Stock-Based Comp., R&D Exp. (Total)	16.28M	25.74M	32.37M	34.33M	33.59M
Stock-Based Comp., G&A Exp. (Total)	27.11M	50.93M	88.52M	43.8M	40.38M
Stock-Based Comp., Other (Total)	-	-	1K	-	-
Total Stock-Based Compensation	43.38M	76.67M	121M	78.13M	73.97M

Fiscal Period: September	2020	2021	2022	2023	2024
Assets
Cash And Equivalents	144M	184M	108M	103M	99.18M
Short Term Investments	172M	183M	268M	293M	578M
Total Cash And Short Term Investments	315M	368M	376M	396M	677M
Accounts Receivable, Total	846K	10.26M	1.41M	-	-
Total Receivables	846K	10.26M	1.41M	-	-
Prepaid Expenses	4.25M	4.36M	7.29M	8.81M	9.54M
Restricted Cash	-	-	-	7.9M	3.5M
Other Current Assets, Total	1.78M	2.19M	20.2M	7.08M	4.97M
Total Current Assets	322M	385M	405M	420M	695M
Gross Property Plant And Equipment	63.32M	88.88M	200M	378M	489M
Accumulated Depreciation	-16.3M	-22.86M	-31.55M	-41.95M	-58.02M
Net Property Plant And Equipment	47.02M	66.02M	169M	336M	431M
Long-term Investments	137M	246M	106M	-	-
Other Intangibles, Total	15.36M	13.66M	11.96M	10.26M	8.56M
Other Long-Term Assets, Total	265K	272K	218K	210K	4.48M
Total Assets	523M	710M	692M	766M	1.14B
Liabilities
Accounts Payable, Total	6.83M	9.46M	2.87M	35.87M	11.39M
Accrued Expenses, Total	13.45M	20.67M	59.11M	57.73M	80.8M
Current Portion of Long-Term Debt	-	-	-	-	-
Current Portion of Leases	1.09M	2.25M	2.78M	10.56M	6.34M
Unearned Revenue Current, Total	19.29M	114M	74.1M	866K	-
Other Current Liabilities	17.26K	-	-	435K	4.64M
Total Current Liabilities	40.68M	147M	139M	105M	103M
Long-Term Debt	-	-	-	268M	735M
Long-Term Leases	20.04M	23.3M	78.8M	105M	111M
Unearned Revenue Non Current	-	131M	55.95M	-	-
Other Non Current Liabilities	-	-	-	-	-
Total Liabilities	60.72M	301M	274M	478M	949M
Preferred Stock Convertible	-	-	-	-	-
Total Preferred Equity	-	-	-	-	-
Common Stock, Total	195K	197K	198K	200K	217K
Additional Paid In Capital	965M	1.05B	1.22B	1.3B	1.81B
Retained Earnings	-504M	-645M	-821M	-1.03B	-1.63B
Comprehensive Income and Other	18.43K	-69K	-136K	-3.22M	4.75M
Total Common Equity	462M	409M	399M	271M	185M
Minority Interest	-	-	19.82M	15.82M	5.62M
Total Equity	462M	409M	418M	287M	191M
Total Liabilities And Equity	523M	710M	692M	766M	1.14B
Supplemental Items
ECS Total Shares Outstanding on Filing Date	103M	105M	106M	107M	124M
ECS Total Common Shares Outstanding	102M	104M	106M	107M	124M
Book Value / Share	4.51	3.92	3.76	2.53	1.49
Tangible Book Value	446M	395M	387M	261M	177M
Tangible Book Value Per Share	4.36	3.79	3.65	2.43	1.42
Total Debt	21.14M	25.54M	81.58M	383M	852M
Net Debt	-294M	-342M	-295M	-12.23M	174M
Debt Equivalent Oper. Leases	50.71M	80.3M	127M	157M	239M
Minority Interest, Total (Incl. Fin. Div)	-	-	19.82M	15.82M	5.62M
Account Code - Inventory Valuation	3	3	3	3	3
Land - (BS)	-	-	3M	3M	3M
Buildings, Total	-	-	-	-	75.99M
Machinery, Total	21.32M	29.16M	40.46M	58.75M	71.93M
Full Time Employees	232	329	397	525	609

Fiscal Period: September	2020	2021	2022	2023	2024
Net Income	-84.55M	-141M	-176M	-205M	-599M
Depreciation & Amortization - CF	4.24M	6.57M	8.72M	10.79M	16.9M
Amortization of Goodwill and Intangible Assets - (CF)	1.7M	1.7M	1.7M	1.7M	1.7M
Depreciation & Amortization, Total	5.94M	8.27M	10.42M	12.49M	18.6M
(Gain) Loss From Sale Of Asset	-	-	-	-	-
(Gain) Loss on Sale of Investments - (CF)	-	-	4.43M	-	80K
Asset Writedown & Restructuring Costs	-	-	-	-	-
Stock-Based Compensation (CF)	43.38M	76.67M	121M	78.13M	73.97M
Other Operating Activities, Total	525K	266K	2.48M	12.31M	18.91M
Change In Accounts Receivable	-184K	-9.41M	8.84M	1.41M	-
Change In Accounts Payable	-821K	2.63M	-6.59M	33M	-5.54M
Change in Unearned Revenues	-63.51M	223M	-113M	-129M	-866K
Change in Other Net Operating Assets	3.83M	10.39M	11.95M	43.23M	31.49M
Cash from Operations	-95.39M	171M	-136M	-154M	-463M
Capital Expenditure	-11.95M	-23.57M	-52.78M	-177M	-141M
Sale of Property, Plant, and Equipment	-	-	-	-	-
Cash Acquisitions	-	-	-	-	-
Investment in Marketable and Equity Securities, Total	-229M	-118M	47.36M	80.58M	-279M
Other Investing Activities, Total	-	-	-	-	-
Cash from Investing	-241M	-142M	-5.42M	-96.16M	-420M
Long-Term Debt Issued, Total	-	-	-	-	392M
Total Debt Issued	-	-	-	-	392M
Long-Term Debt Repaid, Total	-	-	-	-	-
Total Debt Repaid	-	-	-	-	-
Issuance of Common Stock	258M	11.3M	5.19M	3.05M	432M
Repurchase of Common Stock	-	-	-	-	-
Other Financing Activities, Total	-	-	60M	250M	46.87M
Cash from Financing	258M	11.3M	65.19M	253M	871M
Foreign Exchange Rate Adjustments	-	-	-67K	-122K	4.2M
Net Change in Cash	-78.22M	40.85M	-76.43M	2.89M	-8.21M
Supplemental Items
Cash Interest Paid	-	-	-	-	-
Cash Income Tax Paid (Refund)	-103K	2K	2K	-	3.74M
Levered Free Cash Flow	-78.67M	63M	-53.34M	-254M	-440M
Unlevered Free Cash Flow	-78.67M	63M	-53.34M	-243M	-420M
Change In Net Working Capital	57.82M	-94.77M	20.31M	28.77M	-4.67M
Net Debt Issued / Repaid	-	-	-	-	392M

Fiscal Period: September	2020	2021	2022	2023	2024
Profitability
Return on Assets	-13.35	-15.11	-15.91	-17.58	-39.43
Return on Total Capital	-16.02	-20.31	-23.88	-21.89	-43.85
Return On Equity %	-23.96	-32.36	-42.67	-59.33	-254.98
Return on Common Equity	-23.94	-32.36	-43.62	-61.29	-262.48
Margin Analysis
Gross Profit Margin %	100	100	100	100	100
SG&A Margin	64.11	64.12	56.48	45.2	3.51K
EBITDA Margin %	-99.12	-101.79	-69.11	-79.97	-16.4K
EBITA Margin %	-103.94	-106.54	-72.69	-84.45	-16.88K
EBIT Margin %	-105.87	-107.77	-73.39	-85.16	-16.93K
Income From Continuing Operations Margin %	-96.09	-101.85	-72.56	-86.93	-17.17K
Net Income Margin %	-96.09	-101.85	-72.38	-85.27	-16.88K
Net Avail. For Common Margin %	-96.09	-101.85	-72.38	-85.27	-16.88K
Normalized Net Income Margin	-60.06	-63.66	-43.06	-51.95	-10.49K
Levered Free Cash Flow Margin	-89.41	45.55	-21.93	-105.7	-12.39K
Unlevered Free Cash Flow Margin	-89.41	45.55	-21.93	-100.95	-11.83K
Asset Turnover
Asset Turnover	0.2	0.22	0.35	0.33	0
Fixed Assets Turnover	2.51	2.45	2.07	0.96	0.01
Receivables Turnover (Average Receivables)	116.78	24.91	41.7	-	-
Short Term Liquidity
Current Ratio	7.92	2.62	2.92	3.98	6.74
Quick Ratio	7.78	2.58	2.72	3.75	6.57
Operating Cash Flow to Current Liabilities	-2.34	1.17	-0.98	-1.46	-4.49
Days Sales Outstanding (Average Receivables)	3.13	14.65	8.75	-	-
Long Term Solvency
Total Debt/Equity	4.58	6.25	19.5	133.55	445.88
Total Debt / Total Capital	4.38	5.88	16.32	57.18	81.68
LT Debt/Equity	4.34	5.7	18.84	129.87	442.56
Long-Term Debt / Total Capital	4.15	5.36	15.76	55.61	81.07
Total Liabilities / Total Assets	11.62	42.43	39.54	62.49	83.24
EBIT / Interest Expense	-	-	-	-11.19	-18.58
EBITDA / Interest Expense	-	-	-	-9.43	-17.08
(EBITDA - Capex) / Interest Expense	-	-	-	-19.07	-21.45
Total Debt / EBITDA	-0.26	-0.2	-0.54	-2.22	-1.54
Net Debt / EBITDA	3.64	2.62	1.94	0.07	-0.32
Total Debt / (EBITDA - Capex)	-0.23	-0.17	-0.4	-1.1	-1.23
Net Debt / (EBITDA - Capex)	3.17	2.22	1.44	0.03	-0.25
Growth Over Prior Year
Total Revenues, 1 Yr. Growth %	-47.87	57.16	75.89	-1.03	-98.52
Gross Profit, 1 Yr. Growth %	-47.87	57.16	75.89	-1.03	-98.52
EBITDA, 1 Yr. Growth %	-232.89	61.4	19.41	14.53	202.58
EBITA, 1 Yr. Growth %	-245.42	61.1	20	14.99	194.82
EBIT, 1 Yr. Growth %	-252.24	59.98	19.77	14.84	193.21
Earnings From Cont. Operations, 1 Yr. Growth %	-224.39	66.58	25.31	18.57	191.34
Net Income, 1 Yr. Growth %	-224.39	66.58	25	16.59	192.04
Normalized Net Income, 1 Yr. Growth %	-224.07	66.58	17.56	16.32	197.93
Diluted EPS Before Extra, 1 Yr. Growth %	-221.74	61.9	22.8	15.15	160.27
Accounts Receivable, 1 Yr. Growth %	27.87	1.11K	-86.25	-	-
Net Property, Plant and Equip., 1 Yr. Growth %	102.53	40.42	155.36	99.04	28.53
Total Assets, 1 Yr. Growth %	49.35	35.91	-2.56	10.64	48.89
Tangible Book Value, 1 Yr. Growth %	96.2	-11.48	-2.18	-32.46	-32.25
Common Equity, 1 Yr. Growth %	88.8	-11.47	-2.52	-31.91	-31.66
Cash From Operations, 1 Yr. Growth %	-155.13	-279.5	-179.46	13.05	200.77
Capital Expenditures, 1 Yr. Growth %	-0.41	97.18	123.94	234.88	-19.96
Levered Free Cash Flow, 1 Yr. Growth %	-163.6	-180.07	-184.67	319.66	75.06
Unlevered Free Cash Flow, 1 Yr. Growth %	-163.6	-180.07	-184.67	300.77	74.99
Compound Annual Growth Rate Over Two Years
Total Revenues, 2 Yr. CAGR %	133.47	-9.49	66.26	31.94	-87.92
Gross Profit, 2 Yr. CAGR %	133.47	-9.49	66.26	31.94	-87.92
EBITDA, 2 Yr. CAGR %	30.47	46.45	38.82	16.94	86.16
EBITA, 2 Yr. CAGR %	29.86	53.06	39.04	17.47	84.12
EBIT, 2 Yr. CAGR %	29.05	56.06	38.43	17.28	83.5
Earnings From Cont. Operations, 2 Yr. CAGR %	24.61	43.95	44.48	21.89	85.86
Net Income, 2 Yr. CAGR %	24.61	43.95	44.3	20.72	84.53
Normalized Net Income, 2 Yr. CAGR %	24.61	43.76	40.77	19.19	86.16
Diluted EPS Before Extra, 2 Yr. CAGR %	13.59	40.39	41	18.91	73.11
Accounts Receivable, 2 Yr. CAGR %	60.72	293.78	29.1	-	-
Net Property, Plant and Equip., 2 Yr. CAGR %	83.68	68.64	89.36	125.45	59.94
Total Assets, 2 Yr. CAGR %	116.37	42.47	15.08	3.83	28.35
Tangible Book Value, 2 Yr. CAGR %	140.73	31.79	-6.95	-18.72	-32.36
Common Equity, 2 Yr. CAGR %	119.55	29.28	-7.1	-18.53	-31.78
Cash From Operations, 2 Yr. CAGR %	42.13	-0.52	19.2	-5.22	84.39
Capital Expenditures, 2 Yr. CAGR %	189.99	40.13	110.14	173.85	63.72
Levered Free Cash Flow, 2 Yr. CAGR %	63.25	-28.64	-17.66	100.98	169.42
Unlevered Free Cash Flow, 2 Yr. CAGR %	63.25	-28.64	-17.66	96.41	163.15
Compound Annual Growth Rate Over Three Years
Total Revenues, 3 Yr. CAGR %	40.97	104.62	12.95	39.86	-70.5
Gross Profit, 3 Yr. CAGR %	40.97	104.62	12.95	39.86	-70.5
EBITDA, 3 Yr. CAGR %	39.24	40.06	36.82	30.2	60.54
EBITA, 3 Yr. CAGR %	37.35	39.53	41.14	30.51	59.64
EBIT, 3 Yr. CAGR %	36.05	38.63	42.89	30.07	59.18
Earnings From Cont. Operations, 3 Yr. CAGR %	34.98	37.27	37.44	35.27	62.97
Net Income, 3 Yr. CAGR %	34.98	37.27	37.33	34.4	62.06
Normalized Net Income, 3 Yr. CAGR %	34.98	37.27	34.98	33.25	61.76
Diluted EPS Before Extra, 3 Yr. CAGR %	21.36	27.83	34.26	31.79	54.39
Accounts Receivable, 3 Yr. CAGR %	131.92	215.23	28.7	-	-
Net Property, Plant and Equip., 3 Yr. CAGR %	44.72	67.95	93.65	92.53	86.94
Total Assets, 3 Yr. CAGR %	71.26	85.3	25.53	13.58	17.08
Tangible Book Value, 3 Yr. CAGR %	94.19	72.46	19.32	-16.37	-23.5
Common Equity, 3 Yr. CAGR %	78.33	62.2	17.67	-16.24	-23.16
Cash From Operations, 3 Yr. CAGR %	58.54	53.63	-7.68	17.12	39.28
Capital Expenditures, 3 Yr. CAGR %	14.71	155	63.84	145.45	81.74
Levered Free Cash Flow, 3 Yr. CAGR %	51.61	28.75	-24.45	47.89	91.17
Unlevered Free Cash Flow, 3 Yr. CAGR %	51.61	28.75	-24.45	45.64	88.2
Compound Annual Growth Rate Over Five Years
Total Revenues, 5 Yr. CAGR %	196.81	287.47	50.59	71.68	-53.8
Gross Profit, 5 Yr. CAGR %	196.81	287.47	50.59	71.68	-53.8
EBITDA, 5 Yr. CAGR %	1.34	11.33	39.08	30.31	54.75
EBITA, 5 Yr. CAGR %	1.99	11.94	38.02	30.25	56.97
EBIT, 5 Yr. CAGR %	2.11	11.74	36.99	29.66	57.92
Earnings From Cont. Operations, 5 Yr. CAGR %	-1.66	11.5	38.7	30.9	55.08
Net Income, 5 Yr. CAGR %	-1.66	11.5	38.63	30.4	54.56
Normalized Net Income, 5 Yr. CAGR %	1.13	10.49	37.28	29.73	54.3
Diluted EPS Before Extra, 5 Yr. CAGR %	-12.12	0.3	28.86	24.19	48.63
Accounts Receivable, 5 Yr. CAGR %	-	167.41	83.49	-	-
Net Property, Plant and Equip., 5 Yr. CAGR %	59.7	33.82	61.15	88.94	79.39
Total Assets, 5 Yr. CAGR %	31.62	40.83	46.08	46.98	26.65
Tangible Book Value, 5 Yr. CAGR %	39.22	40.02	44.69	27.65	-4.91
Common Equity, 5 Yr. CAGR %	33.19	33.73	37.39	23.15	-5.39
Cash From Operations, 5 Yr. CAGR %	7.74	21.59	41.57	26.65	21.75
Capital Expenditures, 5 Yr. CAGR %	43.41	43.59	46.14	162.38	63.79
Levered Free Cash Flow, 5 Yr. CAGR %	13.79	13.31	18.76	53.85	28.9
Unlevered Free Cash Flow, 5 Yr. CAGR %	13.79	13.31	18.76	52.44	27.69